Negative HIV test at screening
Negative serum pregnancy test at screening
A negative pregnancy test (if female)
FOCBP must have a negative pregnancy test =< 7 days prior to registration on study
Negative serum pregnancy test
Negative serum pregnancy test within 7 days prior to starting treatment
FOCBP must have a negative pregnancy test within 7 days prior to registration on study
Female patients must have a negative pregnancy test
A negative serum pregnancy test
FOCBP must have a negative pregnancy test within 7 days prior to registration on study; NOTE: a negative pregnancy test is also required within 3 days prior to first dose of pembrolizumab and therefore may need to be repeated if screening test is more than 3 days prior to first dose
And have a negative serum pregnancy test at screening
Negative serum pregnancy test
In female, a negative pregnancy test if experiencing menstrual periods.
Negative serum pregnancy test at screening
have a negative serum pregnancy test at the time of enrollment,
Women of child bearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days prior to investigational product administration and a negative urine pregnancy test within the 3 days prior to the first investigational product administration, or a negative serum pregnancy test within the 3 days prior to the first investigational product administration
Negative serum pregnancy test.
FOCBP must have a negative pregnancy test within 7-10 days prior to receiving study drug
Has a negative serum pregnancy test within 7 days prior to starting treatment.
FOCBP must have a negative pregnancy test =< 7 days prior to registration on study
And have a negative serum pregnancy test ? 10 days of cycle 1, day 1 (C1D1)
For WoCBP* negative serum pregnancy test within 7 days of enrollment.
In female, a negative pregnancy test if experiencing menstrual periods
FOCBP must have a negative pregnancy test within 7 days prior to registration\r\n* Note: FOCBP will have to have repeat pregnancy test within 24 hours of starting nivolumab, scheduled for cycle 1 day 1
Negative serum pregnancy test
have a negative serum pregnancy test at screening and before Betalutin injection
A negative Hepatitis B test (HBsAg and anti-HBc) and negative HIV test during screening
Negative serum pregnancy test
Negative serum pregnancy test
Negative pregnancy test
Negative pregnancy test at the time of SRS in any patient who could be pregnant
Pregnancy or breastfeeding; female patients who are post-menarchal must have a documented negative pregnancy test
Negative pregnancy test, if applicable
A negative serum pregnancy test (if female and aged between 18-55 years old).
Negative pregnancy test
FOCBP must have a negative pregnancy test =< 7 days prior to registration
Negative pregnancy test
A negative pregnancy test (if female).
Negative serum pregnancy test
WOCBP must have a negative serum pregnancy test within 14 days prior to the first dose of ipilimumab/nivolumab
A negative serum pregnancy test (if female and aged between 18-55 years old).
Documentation of negative pregnancy test.
Must have a negative serum pregnancy test
Negative pregnancy test at screening
Negative serum pregnancy test; if, on cycle 1 day 1, greater than 72 hours has elapsed since the last negative result, a serum pregnancy test must be repeated and be negative on cycle 1 day 1 (C1D1) for the patient to remain eligible
Negative serum pregnancy test at screening.
Negative serum pregnancy test within 7 days of commencement of treatment in premenopausal women
Negative pregnancy test for WOCBP
Negative pregnancy test (if female in reproductive years)
Negative pregnancy test.
Negative pregnancy test (if female in reproductive years)
Negative pregnancy test if applicable
Subjects with reproductive potential must have a negative pregnancy test within 14 days before randomization
And have a negative blood pregnancy test at the time of screening
And have a negative serum pregnancy test at screening
Negative serum test for pregnancy in premenopausal women
Negative serum pregnancy test.
Post-menarchal female has had negative serum pregnancy test within 7 days prior to enrollment
Women must have a negative serum pregnancy test
A negative serum pregnancy test (if female and aged between 18-55 years old).
WOCBP must have a negative serum pregnancy test within 7 days prior to receiving investigational product and a negative urine pregnancy test on Day 1 of each Cycle;
A negative serum pregnancy test (if female)
Negative pregnancy test
Negative pregnancy test
Negative pregnancy test
Negative pregnancy test
Negative pregnancy test
negative serum pregnancy test
Negative pregnancy test
FOCBP must have a negative pregnancy test within 14 days prior to registration on study
Must have a negative serum pregnancy test at screening and day -1, and
Negative pregnancy test at study registration
Negative pregnancy test
Negative pregnancy test
They are not pregnant (i.e., female patients must have a negative serum pregnancy test at screening);
Pregnancy, confirmed by a negative pregnancy test within 30 days of study enrollment
All WOCBP MUST have a negative pregnancy test prior to first receiving study medication
Negative pregnancy test =< 7 days prior to randomization
has a negative pregnancy test on the day of vaccination, and
has a negative pregnancy test on the day of vaccination, and
Pregnancy or nursing patients will be excluded from the study; a pregnancy test will be done prior to the MR examination for postmenarchal teenage girls, in whom pregnancy may be possible; only patients with a negative pregnancy test will be included in the study
Pregnancy or nursing patients will be excluded from the study; a pregnancy test will be done prior to the MR examination for postmenarchal teenage girls, in whom pregnancy may be possible; only patients with a negative pregnancy test will be included in the study
Determination of pregnancy status: Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to each set of [18F]FLT and [18F] Fluciclovine PET scans; a negative test will be necessary for such patients to undergo research PET imaging
In female patients, negative pregnancy test with no plans to become pregnant during the duration of the study
Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to the research PET scans; the serum pregnancy test must be performed within 48 hours prior to the initial research PET imaging; a negative test will be necessary for such patients to undergo research PET imaging
Determination of pregnancy status: female patients that are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to each set of multi-tracer PET scans; a negative test will be necessary for such patients to undergo research PET imaging
Negative serum pregnancy test
Female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within 48 hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imaging
Determination of pregnancy status: female patients who are not postmenopausal or surgically sterile will undergo a serum pregnancy test prior to baseline and the subsequent set of multi-tracer PET scans; the serum pregnancy test must be performed within 48 hours prior to research PET imaging; a negative test will be necessary for such patients to undergo research PET imaging
Not pregnant and not nursing; therefore, for women of childbearing potential only, a negative (if your test schedule specifically indicates a urine or serum pregnancy test, add that information at this point) pregnancy test done =< 28 days prior to registration is required
Female patients must have a negative pregnancy test (blood or urine) within 14 days prior to registration
WOCBP must have a negative pregnancy test (serum or urine).
Negative serum or urine pregnancy test within 7 days prior to starting treatment
Negative urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Females at reproductive age must have a negative urine pregnancy test prior to entry to this study
Female patients must have a negative urine pregnancy test within 7 days prior to registration; if urine test is positive, it should be followed by serum pregnancy test
FCBP must have a negative serum or urine pregnancy test and agree to birth control.
If female, the subject must have a negative serum or urine pregnancy test at Screening unless meeting non-productive potential criteria.
Either of non-reproductive potential (i.e., post-menopausal by history of age >= 50 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, history of bilateral tubal ligation, or history of bilateral oophorectomy) OR must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; subjects with a negative pregnancy test at screening beyond 72 hours prior to treatment, but who otherwise meet all other criteria, may be registered to trial but must have a repeat negative serum pregnancy test within 72 hours of treatment and such testing may be done on day of first treatment prior to administration
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.
FOCBP must have a negative serum or urine pregnancy test within 14 days prior to registration on study
Pregnancy (assessed by urine HCG)
Female subject of childbearing potential should have a negative urine or serum pregnancy test within 28 days of study registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Pregnancy (positive serum or urine ?HCG test) or breast-feeding
Female of childbearing potential: negative urine or serum pregnancy test, performed within 14 days prior to day 1 of protocol therapy\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative urine or serum pregnancy test done =< 72 hours prior to first treatment, for women of childbearing potential only\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential should have a negative pregnancy test within 10 days prior to on-study date; if a urine or serum test is positive or cannot be confirmed as negative, the other (urine or serum pregnancy test, whichever was not performed first) will be required
Females of childbearing potential must have a negative pregnancy test within 10 days prior to “on study” status; if a urine or serum test is positive or cannot be confirmed as negative, the other (urine or serum pregnancy test, whichever was not performed first) will be required
DONOR: A serum or urine pregnancy test for females of reproductive potential must be conducted within 7 days prior to initiation of apheresis
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only (POCBP)\r\n* NOTE: Serum or urine pregnancy test allowed; if urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential must have a negative pregnancy test (either urine or serum pregnancy test) within 72 hours prior to the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
FOCBP must have a negative serum OR urine pregnancy test =< 7 days prior to registration
Female patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
FOCBP must have a negative pregnancy test (either urine or serum) within 14 days prior to registration
To be performed within 10 business days prior to day 1: Female of childbearing potential: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Within 14 days prior to planned start of treatment: Female of childbearing potential: negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
A negative urine dipstick pregnancy test
Female subject of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible
Female subject of childbearing potential should have a negative urine or serum pregnancy test within 10 days of initiating SBRT; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative urine or serum pregnancy test (female of childbearing potential only)\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
FOCBP must have a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Positive pregnant status confirmed by serum or urine pregnancy test
FOCBP must have a negative pregnancy test (serum or urine) within 7 days prior to registration on study
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)
Patients of childbearing potential must have a negative urine or serum pregnancy test =< 7 days prior to registration\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within 28 days prior to study registration up to the first fraction of radiation; \r\n* Note: if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential (WOCBP) (free from menses for > 2 years, post hysterectomy/oophorectomy, or surgically sterilized) must have a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative a serum pregnancy test will be required to be shown as negative for the patient to be eligible
DONOR: Female subjects must have a negative urine or serum pregnancy test within 10 days prior to taking study medication if of childbearing potential or must be of non-childbearing potential; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible; non-childbearing potential is defined as:\r\n* >= 45 years of age and has not had menses for > 2 years\r\n* Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone (FSH) value in the postmenopausal range upon pretrial (screening) evaluation\r\n* Post-hysterectomy, oophorectomy, or tubal ligation
Female subjects must have a negative urine or serum pregnancy test if of childbearing potential or be of non-childbearing potential; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the subject to be eligible; non-childbearing potential is defined as:\r\n* >= 45 years of age and has not had menses for > 2 years\r\n* Amenorrheic for > 2 years without a hysterectomy and oophorectomy and a FSH value in the postmenopausal range upon pretrial (screening) evaluation\r\n* Post-hysterectomy, oophorectomy, or tubal ligation
Pregnancy (assessed by urine HCG)
Female patients who are at least 10-years-old or are post-menarchal must have a negative serum or urine pregnancy test prior to enrollment
Negative urine pregnancy test and/or serum pregnancy test within 7 days of initiation of therapy
Negative serum or urine pregnancy test
Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at screening
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)
Negative pregnancy test (serum or urine) in premenopausal women
Patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days of enrollment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Have a negative urine pregnancy test at baseline.
Negative blood or urine pregnancy test at screening
For childbearing female patients, negative serum or urine pregnancy test at screening
A negative serum or urine pregnancy test during Screening,
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Negative urine/serum pregnancy test (females only) at the time of screening and within 24 hours of study treatment, if applicable
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female participants of childbearing potential must have a negative serum pregnancy test at screening and negative (serum or urine) pregnancy test within 72 hours before the first study-drug dose; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the participant to be eligible
To be performed within 28 days prior to day 1 of protocol therapy: Female of childbearing potential: negative urine or serum pregnancy test\r\n* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening or who are lactating.
A WOCBP who has a positive urine pregnancy test within 72 hours prior to study treatment start; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Woman of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only\r\n* NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* NOTE: Merck requires an additional pregnancy test if eligibility pregnancy test is > 72 hours prior to first dose
Female subject of childbearing potential should have a negative urine or serum pregnancy per institutional guidelines for high-dose melphalan and autologous transplant; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Females only:\r\n* Urine or serum pregnancy test negative assessed within seven (7) days prior to the start of therapy
And have a negative urine pregnancy test at Screening
Have a negative urine or serum pregnancy test at screening
Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening.
Negative urine/serum pregnancy test, if applicable
Negative serum or urine pregnancy test within 3 days prior to start of study treatment.
Negative urine pregnancy test
Pregnant or breastfeeding women; female study participants of reproductive potential must have a negative urine pregnancy test of enrollment; a serum pregnancy test will be performed within 2 weeks before infusion
Female of childbearing potential only: negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (within 14 days prior to day 1 of protocol therapy)
And have a negative urine or serum pregnancy test at screening
Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry (positive urine tests are to be confirmed by serum test)
Negative urine or serum pregnancy test done =< 7 days prior to registration for females who are post-menarchal
Female patients must be surgically sterile, post-menopausal (for at least 1 year), or have negative results from a pregnancy test performed as follows:\r\n* At screening, on a serum sample obtained within 14 days prior to the first study drug administration, and\r\n* Prior to dosing, on a urine sample obtained on day 1 of treatment if it has been > 7 days since obtaining the serum pregnancy test result
Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.
Female subjects of childbearing potential should have a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
must have a negative urine pregnancy test at Screening, and
Female patient of childbearing potential has a negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; the serum pregnancy test must be negative for the patient to be eligible
Female participant who is post-menarchal must have a negative urine or serum pregnancy test
Positive serum or urine pregnancy test
Patients who are pregnant; pregnancy will be confirmed by negative urine test
Known pregnancy (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment) (Female only)
DONOR: Known pregnancy (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment) (Female only)
Female patients must have a negative urine or serum pregnancy test at screening (pregnancy test not required for patients with bilateral oophorectomy and/or hysterectomy or for those patients who are > 1 year postmenopausal)
The patient is pregnant (confirmed by urine or serum pregnancy test) or lactating
Female patients of childbearing potential (not postmenopausal for at least 12 months and not surgically sterile) must have a negative serum or urine pregnancy test within 14 days of study registration; pregnancy test must be repeated if performed > 14 days before starting study drug
INCLUSION CRITERIA - HPC-A CELL DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 7 days prior to enrollment (if female)
(Female only) negative serum or urine pregnancy test (to be conducted within 7 days prior to enrollment)
(Female only) is not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to admission for transplant)
DONOR: (Female only) is not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment)
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)
Patient is pregnant as confirmed by positive serum or urine pregnancy test within 14 days prior to enrollment
Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)
Negative serum or urine pregnancy test within 7 days prior to and including the morning of day -7 (first potential day of research blood draw and tumor biopsy)
Negative serum or urine pregnancy test at the time of first dose for WOCBP.
DONOR: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)
Negative urine pregnancy test (negative serum confirmatory pregnancy test if urine test is positive)
Pregnant or nursing women; a negative pregnancy test (serum or urine) =< 3 days prior to starting study treatment
Female subjects of childbearing potential must have either a negative urine or a negative serum pregnancy test within seven (7) days of first dose of pembrolizumab; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential, must have either a negative urine or a negative serum pregnancy test within seven (7) days of first dose of pembrolizumab; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
FOCBP must have a negative urine or serum pregnancy test within 14 days prior to registration on study.
Pregnancy: All female patients < 55 years old (yo) will be administered a urine pregnancy test prior to enrollment
Patients who are pregnant; the absence of pregnancy will be confirmed by negative urine test
Minocycline trial only: patients who are pregnant; pregnancy will be confirmed by negative urine test; patients with a positive urine test will be retested for doubling of human chorionic gonadotropin (HCG) 48 hours after the first test; patients without such a rise will be eligible for the study and will be enrolled at the investigator’s discretion
(Female only) Known pregnancy (negative serum or urine pregnancy test to be conducted within 14 days prior to enrollment)
Satisfactory results of screening safety labs, urine pregnancy test and drug test
Pregnancy (assessed by urine HCG)
Negative pregnancy test (urine and blood tests)
Pregnancy (urine hCG)
A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential
Female subjects of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to C11-AMT PET scan; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
And have a negative urine or serum pregnancy test at screening
Female patients must have a negative urine pregnancy test
A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential
Female subjects with reproductive potential must have negative serum or urine pregnancy test
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female subjects of childbearing potential must have a negative serum pregnancy within three days prior to registration for protocol therapy
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Patients who are pregnant; (a negative pregnancy test is required for female patients of childbearing potential)
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 8 days of initiating protocol therapy
Female patients who are pregnant or currently breastfeeding; female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 8 days of initiating protocol therapy
If female of childbearing potential, must have a negative pregnancy test within 7 days of initiating treatment. Childbearing potential is defined by: those who have not been surgically sterilized and/or have had a menstrual period in the past year.
Female subjects of childbearing potential must have a negative serum pregnancy test at screening
Female subjects of childbearing potential must have a negative pregnancy test at screening
Female subjects of childbearing potential must have a negative serum pregnancy test at screening
Female patients must have a negative serum pregnancy test or be of non-childbearing potential.
Negative serum pregnancy test within 7 days prior to the administration of the study drugs for female patients of childbearing potential.
Pregnancy (negative serum pregnancy test to be obtained within 6 days prior to enrollment for subjects of childbearing potential)
Female participants of childbearing potential are to have a negative serum pregnancy test
Female patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.
Female patients of childbearing potential must have a negative serum pregnancy test at the time of enrollment
Has a negative serum pregnancy test within 7 days of first dose of study treatment (female patients of childbearing potential)
Female patients of childbearing potential must have a negative pregnancy test, as measured by serum or urine testing
Female subjects of childbearing potential must be nonpregnant, nonlactating, and have a negative pregnancy test result at Screening and Day 1 of Cycles 1-6.
Within 7 days of enrollment and with 24 h of starting lymphodepleting chemotherapy: Negative serum pregnancy test (female subjects of childbearing potential).
For female subjects of childbearing potential, a negative serum pregnancy test.
For female subjects of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.
Female patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to enrollment; male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment
Female participants of childbearing potential must have negative results for pregnancy test performed:
Female subject of childbearing potential should have a negative pregnancy test within 14 days prior to receiving the first dose of study medication
Female subjects of childbearing age must have a negative serum pregnancy test at study entry
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
Patients of childbearing potential must have a negative pregnancy test within 7 days prior to treatment start to be eligible
Negative pregnancy test within 14 days of day 1 cycle 1 for female patients of childbearing potential.
Female patients of childbearing potential, negative urine pregnancy test done =< 7 days prior to study registration
Female subjects of childbearing potential should have a negative serum pregnancy =< 7 days prior to registration
Female patients of childbearing potential must have a negative pregnancy test < 1 week prior to enrollment.
Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days
Have a negative pregnancy test if a female with childbearing potential
Female patients of childbearing potential must have a negative serum pregnancy test confirmed within 7 days prior to enrollment
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
Negative pregnancy test (urine or serum) for female patients of childbearing potential
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).
Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start
Negative pregnancy test in female patients of childbearing potential
Negative pregnancy test in female patients of childbearing potential
STEP 2: Negative pregnancy test in female patients of childbearing potential
Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to entering this study
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment.
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Negative pregnancy test of the blood within 7 days of starting treatment in female patient of childbearing potential
A negative pregnancy test (if female of childbearing potential).
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment, and
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female participants of childbearing potential must have a negative serum pregnancy test within the 7 days prior to the first study drug administration.
A negative serum pregnancy test, if female of reproductive potential
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have negative serum pregnancy test within 14 days of starting protocol therapy
Female patients of childbearing potential must have a negative pregnancy test
Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of study entry
If female of childbearing potential, serum pregnancy test is negative
For female patients of childbearing potential, have a negative pregnancy test documented prior to randomization.
Negative serum pregnancy test if female and of childbearing potential
Any patients of childbearing potential must have a negative pregnancy test
Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose.
Female patients of childbearing potential must have negative urine pregnancy test no more than 3 days prior to starting study treatment
Female participants must have a negative pregnancy test at screening if of childbearing potential or be of non-childbearing potential
Subject is of childbearing potential and does not have a negative pregnancy test.
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy text result has been obtained
Within 14 days of enrollment: If female of childbearing potential, urine pregnancy test is negative
Female subject of childbearing potential should have a negative pregnancy test or documentation of absence of pregnancy by a gynecologist within 2 weeks of initiating radiation therapy
For female subjects with reproductive potential: a negative serum pregnancy test
Female patient of childbearing potential has a negative serum or urine pregnancy test within 14 days prior to administration of study therapy
Female subject of childbearing potential should have a negative serum pregnancy within 2 weeks prior to starting radiation therapy or undergoing ablation
Female subject of childbearing potential should have a negative serum pregnancy test
Female patients of childbearing age must have negative pregnancy test
Female patients of childbearing potential must have a negative pregnancy test within 14 days of radiation start
For female participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment.
If female of childbearing potential, negative pregnancy test
If a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 hours before enrollment where required
Female patients of childbearing potential must have negative serum pregnancy test =< 21 days prior to starting study treatment
Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
Female patients of childbearing potential must have a negative pregnancy test at screening
Negative serum pregnancy test within 7 days prior to enrollment in female subjects with reproductive potential
If female of childbearing potential, pregnancy test is negative
Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
Patients of childbearing age must have a negative pregnancy test
Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrollment
Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
Female patient who is of childbearing potential must have a negative serum pregnancy test result within 3 weeks prior to starting study drugs.
Female subject of childbearing potential should have a negative serum pregnancy within 28 days prior to receiving the first dose of study medication
Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment
Female patients of childbearing potential must have a negative serum or urine pregnancy test, whichever is considered standard by the institution
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.
If female of childbearing potential, participant presents with a negative blood pregnancy test
Female patients cannot be of childbearing age, or if they are, must have a negative pregnancy test prior to enrollment and be willing to use contraceptives during treatment and continue for 6 additional months
Female patient of childbearing potential has a negative pregnancy test within 14 days prior to the start of study drug.
Female patients who are not of childbearing potential, and female patients of childbearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test within 72 hours prior to start of treatment.
Female patients of childbearing potential must have a negative serum or urine pregnancy test at the time of enrollment
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Female patients of childbearing potential must have a negative serum or urine pregnancy test
NON-PROGRESSED DIPG (STRATUM 2): Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
Female subjects of childbearing age must have a negative serum pregnancy test at study entry
Female patients of childbearing potential must be non-pregnant, non-lactating, and have a negative pregnancy test result prior to enrollment in the study;
If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first dose
If the subject is a female of childbearing potential, has she had a negative serum pregnancy test within the past 21 days?
Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
Female patients of childbearing potential must have a negative serum pregnancy test
Female patient of childbearing potential has a negative pregnancy test within 14 days prior to the start of study drug
If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
Female participants of childbearing potential must have a negative serum pregnancy test
Female subject of childbearing potential must have a negative pregnancy test at screening
Female participants of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG).
Female patients of childbearing age must have a negative pregnancy test
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry
Urine or serum pregnancy test: negative for female patients of childbearing potential
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Pregnancy; female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days; male patients with reproductive potential will be counseled not to procreate during the study
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to starting study drug
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test
Female patients of childbearing potential must have a negative pregnancy test at screening
Female subjects of childbearing potential must have a negative pregnancy test
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to enrollment
A negative serum pregnancy test at baseline, but within 21 days of randomization, for persons of childbearing potential only
Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained < 2 weeks prior to study enrollment
Negative pregnancy test, to be performed on female patients of childbearing potential within 1 week before administration of radioactive material
Negative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC standards & guidelines), from assays obtained < 2 weeks prior to study enrollment; patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the study
Negative serum pregnancy test (female of childbearing potential only)
Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days of enrollment
Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment)
if female of childbearing potential must have a negative pregnancy test within 24 hours of enrollment
If female of childbearing potential, pregnancy test is negative; (in these instances, the patient will need to provide documentation of negative pregnancy test results)
Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to infusion
Criteria 9, Female subjects of childbearing potential should have a negative serum pregnancy test within 1 week prior to enrollment
Female subject of childbearing potential must have a negative pregnancy test within 72 hours prior to enrollment.
Female patients of childbearing potential must have a negative pregnancy test within 1 week prior to beginning study treatment.
Women must not be pregnant or breastfeeding; all females of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a blood or urine test to rule out pregnancy within 2 weeks prior to registration
Pregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Pregnant or breastfeeding - females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Pregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Pregnant or breast feeding; the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
Pregnant or breast feeding; all females of childbearing potential must have a blood or urine pregnancy test within 2 weeks prior to enrollment to rule out pregnancy
If female, patient must not be pregnant or breastfeeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy
Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy
Women must not be pregnant or breast-feeding\r\n* All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy
Pregnant or lactating; the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk; all females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy; women of childbearing age must use appropriate contraceptive method
Pregnant or breast feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
Pregnant or lactating; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
Pregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Pregnant or breast feeding; females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy
Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential at screening
Women must not be pregnant or breast-feeding as the agents used in this study may be teratogenic to a fetus and there is no information on the excretion of the agents or their metabolites into breast milk; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
BIODISTRIBUTION COHORT: Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening
DYNAMIC COHORT: Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening
Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Female patients who are pregnant are not eligible; Note: a pregnancy test is required for female patients of childbearing potential prior to study entry
Patients who are pregnant; pregnancy test is required for female patients of childbearing potential
Female patients who are pregnant are excluded; patients should not be pregnant or plan to become pregnant while on treatment; a pregnancy test prior to enrollment is required for female patients of childbearing potential
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to starting treatment)
Female patients are eligible to enter and participate in the study if they are of: a) Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who: i. has had a hysterectomy ii. has had a bilateral oophorectomy iii. has had a bilateral salpingectomy iv. is post menopausal (total cessation of menses for ? 1 year) b) Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), is not breast feeding, and uses highly effective contraception before study entry and throughout the study until 90 days after the last investigational product administration. Adequate contraception as recommended by the Clinical Trial Facilitation Group (CTFG)
Female research participants of childbearing age must not be pregnant as confirmed by a serum or urine pregnancy test within 1 week of start of treatment; participants must not be breast-feeding
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)
Female subjects must either be of non-reproductive potential, not breast-feeding or must have a negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1.
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients who have menstruated and are of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to registration
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)
Participant is pregnant, breast feeding or planning to become pregnant; (all participants of childbearing potential regardless of method of birth control must have a negative pregnancy test at baseline; a woman is considered not to be of childbearing potential is she has had a hysterectomy, bilateral oophorectomy, or if she is > 55 years of age with >= 2 years of amenorrhea)\r\n* Breastfeeding should be discontinued if the mother is treated with ACTOplus met XR
Pregnant and/or breastfeeding; a negative serum or urine pregnancy test is required at screening for all female patients of childbearing potential
Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate pregnancy prevention (site-specific criteria applying to Avera only)
Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to taking their first dose of BGB324. Male patients and female patients of reproductive potential must practice highly methods of contraception throughout the study and for ? 3 months after the last dose of BGB324.
Female patients of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods while on study therapy and for 12 week following their last dose of study medication.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (females of childbearing potential must have a negative serum pregnancy test within 7 days prior to administration of axitinib)
Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test within 14 days of registration.
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment)
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test
Pregnant females are excluded; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of radiation therapy
Female subjects of childbearing potential must have a negative pregnancy test at screening; childbearing potential is defined as: participants who have not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and/or uterus)
Female subjects of childbearing potential must not be pregnant at screening; female patients must be either postmenopausal, free from menses for >= 2 years, surgically sterilized, or willing to use two adequate barrier methods of contraception to prevent pregnancy, or must agree to abstain from heterosexual activity throughout the study; female patients of childbearing potential must have a negative serum (beta human chorionic gonadotropin [?HCG]) or urine pregnancy test before receiving the first dose of cabozantinib or carfilzomib; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of reproductive potential will be counseled to use effective contraceptive\r\nmeasures to prevent pregnancy during treatment with either cabozantinib or carfilzomib; patients shall be advised not to take cabozantinib or carfilzomib treatment while pregnant or breastfeeding; if a patient wishes to restart breastfeeding after treatment, she will be advised to discuss the appropriate timing with her physician
Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected timeframe of the study, starting from the time of the Screening Visit through 3 months (90 days) after the last OBP-301 administration. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at each visit before administration of OPB-301. A female not of childbearing potential is one who has undergone bilateral oophorectomy or who has had no menses for 12 consecutive months.
Negative urine or serum pregnancy test in females. Male and female patients with reproductive potential must use an approved contraceptive method if appropriate
Female patients of childbearing age must have a negative serum HCG test within 7 days of study enrollment, unless prior hysterectomy or menopause (defined as age ? 55 years and twelve consecutive months without menstrual activity). Female patients should not become pregnant or breast-feed while on this study.
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within 14 days of registration
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial and for 8 weeks after stopping study drug, by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVE)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to study entry; pregnancy test must be repeated if performed > 14 days before administration of MGCD516)
A female who is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 48 hours (Period 1) or 72 hours (Period 2), respectively, after the last dose of blinatumomab (Female subjects of childbearing potential should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test).
Female patients of childbearing potential who have a positive blood or urine pregnancy test at screening
Pregnancy or breast-feeding; female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and 6 months after; all female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 48 hours from starting the conditioning chemotherapy
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum pregnancy test at enrollment
Female participants of childbearing potential have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraception
Pregnant or lactating women; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to the initiation of radiation therapy
Women who are pregnant or lactating; all female patients with reproductive potential must have a negative pregnancy test prior to day 1
Pregnant or breast-feeding female (women of childbearing potential [WOCBP], defined as not post-menopausal for 12 months or without previous surgical sterilization, must have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; barrier contraceptives must be used throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus and sorafenib)
A urine pregnancy test will be performed on each fertile premenopausal female prior to entry into the study; patients with childbearing potential must employ effective contraception during the radiation therapy
Female subjects of childbearing potential must have a negative serum human chorionic gonadotropic (hCG) test within 1 week of Day 1 (pregnancy test not required for subjects with bilateral oophorectomy and/or hysterectomy or for those subjects who are >1 year post-menopausal); and
Pregnant or breast-feeding. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding
Female patients of childbearing age are excluded if they are pregnant as determined with a serum beta HCG no greater than 14 days prior to study registration, or breast-feeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy).
Female subject who is pregnant (as verified by urine test at time of screening) or lactating or of childbearing potential and not using acceptable methods of contraception.
Pregnancy or breastfeeding, or intention of becoming pregnant during the study. Female subjects must either be of non-reproductive potential or have a negative serum pregnancy test result within 14 days prior to initiation of study treatment
Female patients of childbearing potential have positive urine or serum pregnancy test no more than 7 days prior to starting study drug.
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test (within 7 days prior to study registration)
Patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Women of childbearing potential only: negative serum pregnancy test done =< 7 days prior to registration; NOTE: female subjects who are pregnant or nursing are excluded from this study; there is no specific mitigation strategy for vismodegib toxicity; however, male patients should be made aware of it during the consent process; although this effect is expected to be reversible with discontinuation of dosing, long-term effects on male fertility cannot be excluded at this time
Pregnant or breast feeding; the agents used in this study have the potential to harm a fetus; radiation is a known teratogen; there is insufficient information regarding potential for fetal harm during immunotherapy at this time; biological females of childbearing potential must have a negative pregnancy test within 14 days of registration
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of study drug)
Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes and continue use for 8 weeks after completing treatment; hormonal contraceptives are not acceptable as a sole method of contraception
A negative pregnancy test in female patients of childbearing potential; women must not be breast-feeding
Female subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy and on the first day of study drug administration.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; two acceptable forms of contraceptives must be continued throughout the trial by either sex; hormonal contraceptives are not acceptable as a sole method of contraception (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to day 1 of study drug)
Female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* Note: women of child-bearing potential must agree to use 2 methods of birth control, or be surgically sterile, or abstain from heterosexual activity beginning with the screening visit and for the duration of study participation, through 120 days beyond last dose of MK-3475 administration; patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year\r\n* Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to registration\r\n* Childbearing potential is defined as: participants who have not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus)
Pregnant or lactating patients. Patients of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to registration and must implement adequate contraceptive measures during study treatment;
Pregnancy Status Female patients of childbearing potential, must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test.
Female who has been post-menopausal for more than one (1) year or female of childbearing potential agreeing to use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner or combined birth control pills]) Female of childbearing potential must have a negative from Screening until 90 days after last dose of INTUVAX and/or until completed sunitinib treatment whichever occurs later.blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax) and must not be lactating.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; two acceptable forms of contraceptives must be continued throughout the trial by either sex and for 4 months (120 days) following last dose of either drug; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to day 1 of study drug)
Female patients who are pregnant or breastfeeding. Female patients of childbearing potential must have a negative pregnancy test and agree to use adequate contraception for the duration of the trial.
Pregnant or breast-feeding patients are excluded; female patients of childbearing potential must have a negative serum or urine pregnancy test at the time of enrollment; in addition, female patients of childbearing potential must have negative pregnancy tests within 10 – 14 days prior to starting pomalidomide (can use enrollment pregnancy test if within the 10-14 day limit) AND again within 24 hours prior to initiation of pomalidomide; this protocol defines the following childbearing potential risk categories as:\r\n* Female child/young adult of childbearing potential as a female who has:\r\n** Achieved menarche and/or breast development, in Tanner stage 2 or greater\r\n** Has not undergone a hysterectomy or bilateral oophorectomy, or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\r\n* Note: amenorrhea following cancer therapy does not rule out childbearing potential
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)
Female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\r\n* Note: women of child-bearing potential must agree to use 2 methods of birth control, or be surgically sterile, or abstain from heterosexual activity beginning with the screening visit and for the duration of study participation, through 120 days beyond last dose of MK-3475 administration; patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Female participants of childbearing potential must have a negative urine or serum pregnancy test and must be willing to use 2 adequate methods of contraception starting with the screening visit through 120 days after the last dose of pembrolizumab
Female patients of childbearing age must have a negative serum HCG test unless prior hysterectomy or menopause (defined as age ? 55 and twelve consecutive months without menstrual activity). Female patients should not become pregnant or breast-feed while on this study. Sexually active male and female patients should use effective birth control
Female subjects of childbearing potential must not be pregnant or breast-feeding; female subjects of childbearing potential must have a negative serum or urine pregnancy test; (pregnancy test must be repeated within 72 hours prior to the start of therapy)
Patients with reproductive potential (for example, females menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures for the duration of study drug therapy and for at least 30 days after completion of study drug therapy; female patients of childbearing potential must provide a negative pregnancy test (serum or urine) =< 14 days prior to treatment initiation
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus)
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test; women of child-bearing potential must have a negative pregnancy test prior to the first dose of bevacizumab; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following the discontinuation of bevacizumab; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Female patients who are pregnant, breast feeding, or of childbearing potential without a negative pregnancy test prior to baseline; male or female patients of childbearing potential unwilling to use contraceptive precautions throughout the trial and 3 months following discontinuation of study drug; post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib
Pregnant females are excluded; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of radiation therapy
Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to everolimus initiation
Female patients of childbearing potential must have negative serum or urine pregnancy test; patient must not be pregnant or breast feeding
Patients with reproductive potential (eg, females menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures for the duration of study drug therapy and for at least 30 days after completion of study drug therapy; female patients of childbearing potential must provide a negative pregnancy test (serum or urine) =< 14 days prior to treatment initiation
Pregnancy or breast-feeding (women of childbearing potential, any female who has experienced menarche and who has not undergone surgical sterilization or is not post-menopausal with a positive serum pregnancy test)
Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy
A woman of childbearing potential must have a negative serum or urine pregnancy test within 14 days before commencing treatment. Females of reproductive potential must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment); male or female of reproductive potential has agreed to use effective contraception method for duration of study treatment
Pregnancy or breast-feeding (women of childbearing potential, any female who has experienced menarche and who has not undergone surgical sterilization or is post-menopausal with a positive serum pregnancy test
Female subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of study treatment
Female subjects of childbearing age must have a negative urine HCG test unless prior hysterectomy or menopause (defined as age above 55 and twelve months without menstrual activity). Female subjects should not become pregnant or breast-feed while on this study. Sexually active male and female subjects should use effective birth control.
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment)
Pregnant or lactating (female participant of childbearing potential must have negative serum or urine pregnancy test required within 7 days prior to start of treatment)
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding.
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test
If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, then she must practice adequate contraception for 30 days prior to treatment administration, have a negative pregnancy test and continue such precautions for 2 months after completion of the treatment administration series.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes (women of childbearing potential [WOCBP] must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)
If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate con-traception for 30 days prior to treatment administration, have a negative pregnancy test and continue such pre-cautions for two months after completion of the treatment administration series.
Pregnant or breast feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.
Being female and pregnant, breast-feeding or of childbearing potential; (note: lack of childbearing potential for female patients is satisfied by: a) being post menopausal; b) being surgically sterile; c) practicing contraception with an oral contraceptive, intra-uterine device, diaphragm, or condom with spermicide for the duration of the study; or d) being sexually inactive; confirmation that the patient is not pregnant will be established by a negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of enrollment
Female subject of childbearing potential is neither pregnant nor lactating and must have a negative pregnancy test at the screen visit and a negative pregnancy test before dosing. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device (IUD), sexual abstinence, vasectomy or vasectomized partner) for the duration of the study
Female participant of childbearing age must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of eligibility) or lactating
All female patients of childbearing potential including those who are within 1 year of last menstrual period will be required to take a pregnancy test during screening, enrollment and at week 0, 4, 8 and 12
Individuals not pregnant at enrollment; female subjects of childbearing potential will undergo a pregnancy test prior to imaging
Individuals not pregnant at enrollment; female subjects of childbearing potential will undergo a pregnancy test prior to imaging
Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done)
Pregnancy (if a female is of childbearing potential—defined as a premenopausal female capable of becoming pregnant-a pregnancy test should be done)
